Investors & Media

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
06/05/17Flex Pharma Announces Executive Leadership Transition
-- Christoph Westphal to Step Down as CEO and Will Continue as Chair of the Board -- -- Board Appoints Flex Executive William McVicar as Interim CEO -- BOSTON--(BUSINESS WIRE)--Jun. 5, 2017-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases... 
Printer Friendly Version
06/02/17Flex Pharma’s Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium
-- US Phase 2 Trial of FLX-787 in CMT Patients to Start This Summer -- BOSTON--(BUSINESS WIRE)--Jun. 2, 2017-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ:FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Charcot-Marie-... 
Printer Friendly Version
05/30/17Flex Pharma Presenting at Upcoming Investor Conferences in June 2017
BOSTON--(BUSINESS WIRE)--May 30, 2017-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Charcot-Marie-Tooth (CMT), today announced that it will present at the following upcoming investor... 
Printer Friendly Version
05/03/17Flex Pharma Reports First Quarter 2017 Financial Results
-- FDA Clears IND for FLX-787 to Commence US Phase 2 Trial in ALS -- -- US Phase 2 Trials in ALS and CMT Expected to Commence Summer 2017 -- Conference Call Scheduled Today at 8:45 a.m. ET BOSTON--(BUSINESS WIRE)--May 3, 2017-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated with sev... 
Printer Friendly Version
04/26/17FDA Clears Flex Pharma's FLX-787 to Commence US Phase 2 Trial in ALS Under IND
BOSTON--(BUSINESS WIRE)--Apr. 26, 2017-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), focused on developing treatments for cramps and spasms associated with the severe neurological diseases of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), today announced that the Company's investigational new drug (IND) application for FLX-787 for patients wi... 
Printer Friendly Version
04/19/17Flex Pharma Presents Human Efficacy Data on FLX-787 at the American Academy of Neurology Annual Meeting
-- TRPA1, Pharmacological Target of FLX-787, Genetically Linked to Human Muscle Cramp Fasciculation Syndrome by Independent Researchers -- BOSTON--(BUSINESS WIRE)--Apr. 19, 2017-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), focused on developing treatments for cramps and spasms associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), today announced that h... 
Printer Friendly Version
04/05/17Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development
BOSTON--(BUSINESS WIRE)--Apr. 5, 2017-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), focused on developing treatments for cramps and spasms associated with severe neurological diseases, today announced the appointment of William K. McVicar, Ph.D., as President of Research and Development. Dr. McVicar brings to Flex Pharma approximately 30 years of clinical development experience, most recently serving as Chief Scientif... 
Printer Friendly Version
03/08/17Flex Pharma Reports Year End 2016 Financial Results
-- IND Submission for FLX-787 On Track for H1 2017 -- -- Phase 2 ALS & CMT Studies with FLX-787 Planned to Initiate This Year -- -- Successful Launch Year for HOTSHOT® Consumer Brand; Revenue Exceeds Expectations -- Conference Call Scheduled Today at 8:30 a.m. ET BOSTON--(BUSINESS WIRE)--Mar. 8, 2017-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovat... 
Printer Friendly Version
03/01/17Flex Pharma to Report Fourth Quarter and Full Year 2016 Results on March 8, 2017
BOSTON--(BUSINESS WIRE)--Mar. 1, 2017-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), announced today that it will report its financial results for the fourth quarter and year ended December 31, 2016 ... 
Printer Friendly Version
02/07/17Flex Pharma to Present at the BIO CEO & Investor Conference
BOSTON--(BUSINESS WIRE)--Feb. 7, 2017-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today announced that Company management will present a corporate overview at the 2017 BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 10:00 a.m. A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at www.flex-pharma.com. Please log on to the... 
Printer Friendly Version
01/24/17Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases
-- Additional Proof-of-Concept Phase 2 Studies Planned to Initiate in 2017 -- -- Exploratory Phase 2 MS Study Results by Year End 2017 -- BOSTON--(BUSINESS WIRE)--Jan. 24, 2017-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it is prioritizing its clinical programs in the severe neurological diseases of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and peripheral ... 
Printer Friendly Version